Dogwood Therapeutics News

Maxim Group Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsNov 8 13:32 ET

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

TipRanksNov 8 12:37 ET

H.C. Wainwright Maintains Virios Therapeutics(VIRI.US) With Hold Rating, Maintains Target Price $5

Moomoo NewsOct 8 20:32 ET

Maintaining Hold on Virios Therapeutics Amid Merger and Clinical Development Uncertainties

TipRanksOct 8 06:20 ET

Virios Therapeutics Analyst Ratings

BenzingaAug 9 17:19 ET

Buy Rating for Virios Therapeutics Amid Promising Long COVID Treatment and Legislative Tailwinds

TipRanksAug 9 13:07 ET

Hold Rating Maintained for Virios Therapeutics Amidst Financial Uncertainty and Pipeline Prospects

TipRanksAug 9 08:23 ET

Maxim Group Maintains Virios Therapeutics(VIRI.US) With Buy Rating, Maintains Target Price $1

Moomoo NewsJul 24 13:32 ET

Optimistic Buy Rating for Virios Therapeutics as IMC-2 Advances in Clinical Trials With Promising Phase 2 Results

TipRanksJul 24 13:29 ET

Virios Therapeutics Analyst Ratings

BenzingaJun 20 07:48 ET

Maintaining Hold on Virios Therapeutics Amid Financial Strains and Clinical Development Risks

TipRanksMay 13 06:35 ET

Virios Therapeutics: A Hold Rating With a New Price Target Amidst Clinical and Financial Challenges

TipRanksMar 6 06:46 ET

Analysts Offer Insights on Healthcare Companies: Portage Biotech Inc (PRTG) and Virios Therapeutics (VIRI)

TipRanksSep 20, 2022 06:35 ET

Virios Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow JonesSep 20, 2022 06:34 ET

Virios Therapeutics Analyst Ratings

Benzinga Analyst RatingsSep 20, 2022 06:24 ET

H.C. Wainwright Keeps Their Buy Rating on Virios Therapeutics (VIRI)

TipRanksAug 15, 2022 06:20 ET